A Novel Targeted Therapy System for Cervical Cancer:  Co-Delivery System  of  Antisense LncRNA of MDC1 and Oxaliplatin Magnetic Thermosensitive Cationic Liposome Drug Carrier

Medicine (General) cervical cancer Mice, Nude antisense lncrna of mdc1 Apoptosis Cell Cycle Proteins 03 medical and health sciences R5-920 Drug Delivery Systems International Journal of Nanomedicine Cell Movement Cations Cell Line, Tumor Animals Humans Molecular Targeted Therapy Original Research Adaptor Proteins, Signal Transducing Cell Proliferation Drug Carriers Mice, Inbred BALB C 0303 health sciences Magnetic Phenomena oxaliplatin targeted therapy 3. Good health Gene Expression Regulation, Neoplastic Oxaliplatin Drug Liberation Liposomes magnetic thermosensitive cationic liposome Female
DOI: 10.2147/ijn.s258316 Publication Date: 2021-02-12T14:02:55Z
ABSTRACT
Background: This study was aimed to prepare a novel magnetic thermosensitive cationic liposome drug carrier for the codelivery of Oxaliplatin (OXA) and antisense lncRNA MDC1 (MDC1-AS) Cervical cancer cells evaluate efficiency this its antitumor effects on cancer. Methods: Thermosensitive liposomes were prepared using thin-film hydration method. The OXA MDC1-AS vectors loaded into system, in vitro release activity, regulating MDC1, cytotoxicity, vivo activity determined. Results: system had desirable targeted delivery efficacy, release, MDC1. Codelivery enhanced inhibition cervical cell growth vivo, compared with single delivery. Conclusion: can be applied combined chemotherapy gene therapy Keywords: liposome, oxaliplatin, therapy,
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (46)
CITATIONS (33)